Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Delcath Systems Inc (DCTH)

Delcath Systems Inc (DCTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Delcath Systems Announces a Comparative Study of Chemosat and SIRT Published in the Journal Cancers PR Newswire - Mon Oct 16, 2023

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 7.88 (-0.38%)
Delcath Systems to Participate in the Lytham Partners Fall 2023 Investor Conference PR Newswire - Tue Oct 10, 2023

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 7.88 (-0.38%)
Delcath Systems to Participate at the Roth MKM 2023 Healthcare Opportunities Conference on October 12, 2023 PR Newswire - Tue Oct 3, 2023

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 7.88 (-0.38%)
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Wed Sep 27, 2023

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and...

DCTH : 7.88 (-0.38%)
A Retrospective Comparative Study of Chemosat and SIRT Presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting PR Newswire - Mon Sep 11, 2023

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 7.88 (-0.38%)
Delcath Systems to Participate at the H.C. Wainwright 25th Annual Investor Conference on September 12 and 13, 2023 PR Newswire - Tue Sep 5, 2023

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 7.88 (-0.38%)
Delcath Systems, Inc. Announces Additional $35 Million in Funding Tied to the FDA Approval of HEPZATO KIT™ PR Newswire - Fri Sep 1, 2023

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 7.88 (-0.38%)
Wall Street - shutterstock_1321462394
Stock Index Futures Plunge on Pressure from Rising Bond Yields, China Data Disappoints Barchart - Tue Aug 15, 2023

September S&P 500 futures (ESU23) are down -0.61%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.48% this morning as market participants digested the latest U.K. employment data, which fueled...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
NVDA : 126.95 (-1.04%)
X : 38.76 (-1.10%)
MNDY : 247.62 (+1.77%)
TSLA : 250.03 (+1.48%)
KEY : 13.97 (-2.10%)
CMA : 49.97 (-0.75%)
HD : 335.27 (+0.49%)
SU : 37.72 (-3.36%)
ALC : 89.28 (+1.30%)
A : 126.24 (+0.09%)
Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma PR Newswire - Mon Aug 14, 2023

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 7.88 (-0.38%)
Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update PR Newswire - Wed Aug 9, 2023

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and...

DCTH : 7.88 (-0.38%)

Barchart Exclusives

3 Standout Stocks to Buy for Q3 2024 Barchart - 33 minutes ago
As we enter the third quarter of 2024, here are three promising stocks investors could consider buying. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot